Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia
- PMID: 26118462
- PMCID: PMC5323257
- DOI: 10.1016/j.mehy.2015.06.011
Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia
Abstract
Schizophrenia is a severe and chronic neuropsychiatric disorder which affects 1% of the world population. Using the brain imaging technique positron emission tomography (PET) it has been demonstrated that persons with schizophrenia have greater dopamine transmission in the striatum compared to healthy controls. However, little progress has been made as to elucidating other biological mechanisms which may account for this hyperdopaminergic state in this disease. Studies in animals have demonstrated that insulin receptors are expressed on midbrain dopamine neurons, and that insulin from the periphery acts on these receptors to modify dopamine transmission in the striatum. This is pertinent given that several lines of evidence suggest that insulin receptor functioning may be abnormal in the brains of persons with schizophrenia. Post-mortem studies have shown that persons with schizophrenia have less than half the number of cortical insulin receptors compared to healthy persons. Moreover, these post-mortem findings are unlikely due to the effects of antipsychotic treatment; studies in cell lines and animals suggest antipsychotics enhance insulin receptor functioning. Further, hyperinsulinemia - even prior to antipsychotic use - seems to be related to less psychotic symptoms in patients with schizophrenia. Collectively, these data suggest that midbrain insulin receptor functioning may be abnormal in persons with schizophrenia, resulting in reduced insulin-mediated regulation of dopamine transmission in the striatum. Such a deficit may account for the hyperdopaminergic state observed in these patients and would help guide the development of novel treatment strategies. We hypothesize that, (i) insulin receptor expression and/or function is reduced in midbrain dopamine neurons in persons with schizophrenia, (ii) basal insulin should reduce dopaminergic transmission in the striatum via these receptors, and (iii) this modulation of dopaminergic transmission by basal insulin is reduced in the brains of persons with schizophrenia.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Conflict of interest statement
The authors report no biomedical or financial conflicts of interest relevant to the proposed hypotheses.
Figures
Similar articles
-
Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.Neuropsychopharmacology. 2008 Dec;33(13):3111-25. doi: 10.1038/npp.2008.33. Epub 2008 Apr 16. Neuropsychopharmacology. 2008. PMID: 18418366
-
The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia.Neuropsychopharmacology. 2006 May;31(5):1027-35. doi: 10.1038/sj.npp.1300931. Neuropsychopharmacology. 2006. PMID: 16237387
-
Novel pharmacological approaches to the treatment of schizophrenia.Dan Med Bull. 2000 Jun;47(3):151-67. Dan Med Bull. 2000. PMID: 10913983 Review.
-
Striatal and extrastriatal dopamine release in the common marmoset brain measured by positron emission tomography and [(18)F]fallypride.Neurosci Res. 2015 Dec;101:1-5. doi: 10.1016/j.neures.2015.07.008. Epub 2015 Jul 29. Neurosci Res. 2015. PMID: 26232153
-
Actions and Consequences of Insulin in the Striatum.Biomolecules. 2023 Mar 11;13(3):518. doi: 10.3390/biom13030518. Biomolecules. 2023. PMID: 36979453 Free PMC article. Review.
Cited by
-
Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial.Diabetes Obes Metab. 2017 Feb;19(2):162-171. doi: 10.1111/dom.12795. Epub 2016 Nov 14. Diabetes Obes Metab. 2017. PMID: 27717222 Free PMC article. Clinical Trial.
-
Association between polymorphism rs2421943 of the insulin-degrading enzyme and schizophrenia: Preliminary report.J Clin Lab Anal. 2023 Jul;37(13-14):e24949. doi: 10.1002/jcla.24949. Epub 2023 Jul 28. J Clin Lab Anal. 2023. PMID: 37515308 Free PMC article.
-
Novel Approaches Used to Examine and Control Neurogenesis in Parkinson's Disease.Int J Mol Sci. 2021 Sep 4;22(17):9608. doi: 10.3390/ijms22179608. Int J Mol Sci. 2021. PMID: 34502516 Free PMC article. Review.
-
Aberrant connectivity in the hippocampus, bilateral insula and temporal poles precedes treatment resistance in first-episode psychosis: a prospective resting-state functional magnetic resonance imaging study with connectivity concordance mapping.Brain Commun. 2024 May 4;6(3):fcae094. doi: 10.1093/braincomms/fcae094. eCollection 2024. Brain Commun. 2024. PMID: 38707706 Free PMC article.
-
Potential role of insulin on the pathogenesis of depression.Cell Prolif. 2020 May;53(5):e12806. doi: 10.1111/cpr.12806. Epub 2020 Apr 13. Cell Prolif. 2020. PMID: 32281722 Free PMC article. Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous